A $40B / Year Problem
Arrhythmias and Heart failure are complex and challenging condition that affects millions of patients worldwide. It's a condition in which the heart muscle, responsible for pumping blood throughout the body, gradually loses its strength and efficiency.
Cardiac Arrhythmia and Heart Failure are one
of the biggest healthcare problems.
Solution
Pioneering Cardiac Monitoring with Under-the-Skin Implantation.
Future Cardia is at the forefront of cardiac monitoring, offering a simple 2 minute office procedure that redefines how we care for heart health. This innovative method combines simplicity, precision, and high patient compliance for a long-term monitoring solution. Our under-the-skin approach brings the accuracy and high compliance that Wearable and Heart Procedure Devices lack, all seamlessly integrated with existing reimbursement structures.
Class II, 510K device with a short regulatory process, with an existing insurance coverage.
Meet Our Team
200 Years of Combined Expertise In Cardiac Devices Development
Jae Bang
CEO
Randy Brase
VP R&D Manufacturing
Deb Kridner
VP Clinical & Regulatory
John Melquist
VP QA
Our Advisors
Professor Frits Prinzen
PhD from Maastricht University
Cardiac Hemodynamics Scientist with expertise in Heart Failure and Cardiac Mechanics.
Dr. Toshi Okabe
MD from University of Tokyo
Cardiologists with specialties in Cardiac Arrhythmias and Electrophysiology, currently practicing at Ohio State University.
Dimitrios Georgakopoulos
PhD from Johns Hopkins
Chief Science Officer with over 25 years of expertise in Heart Failure and Cardiac Hemodynamics
Dr. Dan Burkhoff
PhD from Columbia University
World renowned Cardiologist and a Scientist with expertise in Med Tech Startups and Heart Failure.
Dr. Kevin Heist
MD PhD from Stanford
Associate Professor of Medicine, Harvard Medical School
Anatoly Yakovlev
PhD from Stanford
Biomedical engineer with expertise in Neuromodulations and Machine Learning.
Dr. David Kraus
MD from University of Tennessee
Top Heart Failure and Cardiac Transplant Cardiologist with track record of multiple successful landmark clinical trials.
Partners
Thank you to the following partners who are supporting us along the way
Current state of Acute Heart Failure treatment is excellent is US and Europe, however, chronic management of Heart Failure have eluded us for many decades. Costing $40B (total direct and indirect) in US alone (AHA, Feb 2010). One of the costliest health care expenditures we have. Europe is facing the same problem.
— Jae Bang, CEO of Future Cardia
Reasons To Invest
With your help, we can build the most comprehensive cardiac monitor to tackle
a $40B a year ER and Hospitalization problem
200 years of combined expertise with multiple exits and two IPO
$11M previously raised by notable
angel investor group and equity crowdfunding
A Stanford StartX company, a
member of Johnson and
Johnson's JLABS
